Independent Drug Value Assessment Act
Latest action · Nov 17, 2022 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedNov 16, 2022
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Independent Drug Value Assessment Act
This bill requires the Office of the Assistant Secretary for Planning and Evaluation to contract with outside entities to conduct independent value assessments of approved drugs (i.e., economic analysis of the benefits to patients and the health care system).
Cosponsors 2
Members who signed on, in the order they did. All signed on Nov 16, 2022.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-NY | Jerrold Nadler | Original | Nov 16, 2022 |
| D-CA | Katie Porter | Original | Nov 16, 2022 |
Actions 3
Everything that happened, newest first.
- Nov 17, 2022Referred to the Subcommittee on Health.
- Nov 16, 2022Introduced in House
- Nov 16, 2022Referred to the House Committee on Energy and Commerce.
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Nov 16, 2022Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov.